Tramal

Quick links to important sections

Tramal

Selected form

Treatment option: Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tramal

Quick Facts

Property Description
Active ingredient Tramadol Hydrochloride (INN)
Form Oral tablets/capsules, Injection solution
Pharmacological class Opioid analgesic, Centrally acting
Common use Management of moderate to moderately severe pain
Origin Synthetic compound

What Kind of Medicine is Tramal and its Classification?

Tramal is a synthetic, centrally acting analgesic with the active ingredient being Tramadol Hydrochloride, used specifically for effective pain management. It is formally classified as an opioid analgesic, yet it is frequently recognized as an atypical opioid due to its unique profile within its class.


Tramadol is a manufactured synthetic compound that operates on the central nervous system. Its potent action necessitates its designation as a prescription-only medicine and, in many jurisdictions, its classification as a controlled substance. This formulation, available under several trade names, is frequently employed for chronic pain conditions and is recognized as a key component for managing pain globally.

Composition and Available Pharmaceutical Forms

The core composition of Tramal is the single-entity product Tramadol Hydrochloride, prepared with pharmaceutical excipients to create various forms for patient use. The drug is most frequently available in oral solid preparations, such as tablets and capsules, and parenteral preparations, which include injection solutions.


The availability includes both immediate-release formulations and specialized extended-release preparations. The extended-release form is particularly relevant for adults requiring around-the-clock pain management for an extended period. The drug is also notable for being commonly formulated as a combination tablet with Paracetamol (Acetaminophen), a unique feature among its class.

Regulatory References

  1. Model List of Essential Medicines

What side effects are possible with Tramal?

Possible Side Effects and Safety Information

The safety profile of Tramadol Hydrochloride is formally categorized in regulatory documents, outlining both common adverse reactions and serious safety considerations. The most frequently observed effects relate primarily to the central nervous system and the gastrointestinal system.

Adverse Reaction Classification

Side effects are classified by their reported frequency in official labeling:

Classification Examples of Reactions
Very Common (More than 1 in 10) Nausea, Dizziness
Common (1 to 10 in 100) Headache, Somnolence (drowsiness), Vomiting, Constipation, Dry mouth, Sweating, Fatigue
Uncommon (1 to 10 in 1,000) Cardiovascular effects (e.g., Palpitations, Tachycardia), Skin reactions
Rare (1 to 10 in 10,000) Seizures, Respiratory Depression, Anaphylaxis, Psychiatric disturbances

Serious Adverse Reactions and Safety Constraints

Official regulatory texts specifically highlight certain serious risks. These include the potential for Respiratory Depression, the risk of Seizures (which is elevated at higher doses), and the possible development of Serotonin Syndrome when used with other serotonergic medicines. The risk of developing physical and psychological dependence is formally recognized, particularly with long-term exposure.

Safety constraints and limitations are documented for specific populations. For instance, the labeling notes a need for caution in older adults and patients with renal impairment. The medication is generally restricted or contraindicated in cases of severe hepatic failure, uncontrolled epilepsy, or severe respiratory depression. Some adverse effects, such as nausea and dizziness, are explicitly noted in regulatory documents as being more common during the initiation of treatment.

Overdose and Emergency Response

Overdose with the active substance, Tramadol Hydrochloride, is officially documented as presenting with a range of severe clinical manifestations. The primary, life-threatening concern noted in regulatory documents is profound sedation and respiratory depression, which can rapidly progress to hypoxia, coma, and death. Additional systemic signs recorded in official information include severe hypotension, bradycardia, and cardiac arrest. Neurological toxicity may include seizures (convulsions) and the manifestation of Serotonin Syndrome symptoms, such as autonomic instability and altered mental status.

Immediate Medical Help Required

Urgent medical attention must be sought immediately if an overdose is suspected, due to the critical risk of fatal outcomes. Official regulatory warnings stress that accidental ingestion of even a single dose, especially by a child, can result in a fatal overdose. Naloxone, an opioid antagonist, is the emergency treatment indicated for the reversal of opioid-induced respiratory depression. Overdose management requires prompt symptomatic and supportive treatment alongside continuous monitoring for respiratory and central nervous system effects. The official profile notes that elderly, cachectic, or debilitated patients are at a higher risk for serious respiratory depression.

Therapeutic Uses of Tramal

Tramal is commonly used to manage pain that is classified as moderate to moderately severe. It is generally applied in settings where symptoms related to physical discomfort create noticeable physiological strain, and is relevant when supportive symptom management is appropriate because symptoms are refractory to initial non-opioid approaches.


Targeting Moderate to Moderately Severe Pain

This medication is relevant for easing symptoms that become temporarily overwhelming and is used when symptoms interfere with daily functioning. It is applied across domains where additional symptomatic support is needed, such as in the immediate postoperative context or following a severe injury. This supportive relief may help patients cope more steadily with difficult episodes. Key therapeutic areas involve conditions such as osteoarthritis and certain types of chronic low back pain, along with short-term, acute pain relief.

“This medicine is used for managing symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load during symptomatic periods.”


Sustained Relief for Chronic Conditions

Tramal is considered relevant in conditions characterized by periods of heightened symptoms and ongoing discomfort, including the long-term management of certain chronic pain conditions. The application of this medicine is relevant in contexts requiring sustained symptomatic support. This may assist with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods.

Quick Fact Relief for Symptom
Symptom Level Moderate to moderately severe pain
Common Contexts Postoperative care, chronic pain management
Patient Benefit Supports maintenance of functional stability

Eligibility and Restrictions for Use

The eligibility to use Tramal (Tramadol) is strictly defined by regulatory documents based on age, existing health conditions, and concurrent medication use. The standard labeled population for use is Adults (18 years and older).


Absolute Non-Eligibility (Contraindicated)

Use is strictly prohibited for certain groups as defined in official labeling, including:

  • Children younger than 12 years of age.
  • Adolescents younger than 18 years undergoing post-operative management for tonsillectomy or adenoidectomy.
  • Patients with significant respiratory depression or acute, severe bronchial asthma.
  • Patients currently using or who have recently stopped taking Monoamine Oxidase Inhibitors (MAOIs).
  • Individuals with uncontrolled epilepsy or known hypersensitivity to the drug.

Populations Requiring Conditional Use

  • Organ Impairment: Use is generally not recommended in severe hepatic or severe renal impairment, particularly for extended-release formulations.
  • Older Adults: Patients over 75 years of age must be treated with caution due to the potential for prolonged drug elimination.
  • Reproductive Status: Use is not recommended during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome (NOWS), and is generally not recommended while breastfeeding.
  • Addiction Risk: The medicine should not be prescribed to patients considered addiction-prone or suicidal.

What should I know about interactions with other medicines?

The regulatory interaction profile for this medicine is structured around combinations that are formally prohibited and those that alter drug exposure or increase serious pharmacodynamic risk. Official documentation specifies combinations that are strictly contraindicated, mandatory separation windows, and the classification of pharmacokinetic and pharmacodynamic interactions.

Interaction Type Interacting Substances/Restrictions
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs): Prohibited concurrently or within 14 days of cessation. Acute intoxication with alcohol, hypnotics, or other opioids is also formally contraindicated.
Pharmacodynamic Risk Serotonergic drugs (SSRIs, Triptans): Documented enhanced risk of serotonin syndrome and seizures. CNS depressants: Increased risk of profound sedation and respiratory depression.
Metabolic Exposure Alterations CYP3A4 Inducers (e.g., Carbamazepine): Markedly decrease serum concentrations, which may reduce the intended effect. CYP2D6 Inhibitors (e.g., Fluoxetine): Increase exposure to the medicine, but decrease the active metabolite (M1) concentration.
Other Documented Interactions Coumarin derivatives (e.g., Warfarin): Isolated reports of increased International Normalized Ratio (INR) and bleeding events.

This profile emphasizes two key areas: the elevated potential for serotonin syndrome when co-administered with serotonergic agents, and the risk of respiratory depression with other CNS depressants, both formally classified as high-risk pharmacodynamic interactions. Furthermore, the official label notes that variations in CYP2D6 metabolism, such as in ultra-rapid metabolizers, may lead to altered active metabolite levels, necessitating population-specific cautions.

Mechanism of Action

How Tramal Works

Tramal operates through a unique dual mechanism that modulates nociceptive processing across two complementary central pathways, resulting in modulation of nociceptive signaling.


Opioid Receptor Activation and Metabolic Dependence

This domain encompasses the action on the μ-Opioid Receptor (MOR), which is primarily activated by the metabolite, O-desmethyltramadol (M1), which possesses high affinity for the receptor. The formation of this metabolite is reliant on the CYP2D6 enzyme, introducing a degree of metabolic dependence to the mechanism. Activation of the MOR initiates an inhibitory cascade, which suppresses the central transmission of ascending nociceptive signals and functionally modulates the cough reflex center.


Non-Opioid Monoaminergic Pathway Enhancement

This pathway involves the parent drug directly inhibiting the reuptake of the neurotransmitters Norepinephrine and Serotonin by blocking their respective transporters. This inhibition increases the concentration of these monoamines in the synaptic cleft, potentiating the descending inhibitory system that actively modulates nociceptive input at the spinal cord level.


Synergistic Physiological Modulation

When the formulation includes an additional central analgesic (e.g., Paracetamol), the combination of mechanistically distinct central pathways results in a synergistic pharmacological interaction, leading to a widespread modulation of central nociceptive processing.

Dosage and Administration Information

Tramadol Hydrochloride, marketed as Tramal, is administered via two primary methods: the oral route (using immediate-release or extended-release tablets/capsules) and the parenteral route (intravenous, intramuscular, or subcutaneous injection). The choice of route and formulation dictates the required administration schedule.

Standard Administration Parameters

Formulation Frequency Pattern Maximum Daily Dose (Adults)
Immediate-Release (IR) Every 4 to 6 hours as needed 400 mg
Extended-Release (ER) Once daily (every 24 hours) Up to 300 mg

The typical starting dose for Immediate-Release formulations is 50 mg to 100 mg, and this may be taken with or without food. The total daily intake must not exceed the specified maximum for the formulation used.

Special Procedural Instructions

Extended-release tablets must be swallowed whole and must not be crushed, chewed, or divided, as this risks compromising the sustained-release mechanism. The parenteral injection solution is typically administered slowly over several minutes.

Dose adjustments are required for certain populations. For adults over 75 years, the maximum daily dose is generally restricted to 300 mg. Individuals with severe renal or hepatic impairment must extend the dosing interval of the immediate-release form to 12 hours to account for altered clearance. Treatment is intended for the shortest necessary duration, and any discontinuation following prolonged use requires a gradual dose reduction (tapering).

Recent Clinical Evidence

Research evidence / Overview of studies for Tramal

Evidence for Use in Acute Pain Management

Tramal (tramadol) was evaluated in research exploring how symptoms change over time relevant in trials assessing short-term or episodic symptom patterns, including those related to surgical or dental procedures. Researchers primarily conducted short-term Randomized Controlled Trials (RCTs) and systematic reviews to measure outcomes related to physical discomfort and monitored the use of rescue pain medication. The short-term research describes patterns observed in the studies where studies reported how symptoms evolved in the observed populations.

However, the nature of acute pain studies means the follow-up durations were limited. This research focuses on the immediate post-procedure period, meaning there is limited information for long-term outcomes related to pain that persists or transitions into a chronic condition. Data for certain groups, such as those with complex health issues or children, are still emerging within the controlled trial setting.


Evidence for Use in Chronic Non-Cancer Pain

Tramal was studied for use in research exploring how symptoms change over time related to moderate to moderately severe pain, characteristic of conditions marked by functional limitations, such as osteoarthritis and certain types of chronic low back pain. Studies explored the extended-release forms, with most trials classified as intermediate-term RCTs that typically lasted up to 12 or 16 weeks.

These studies monitored patient-reported outcomes describing perceived discomfort and used functional scales to capture outcomes reflecting daily functioning or activity level. Scientific reviews indicate that the reported data show patterns related to physical discomfort that did not consistently meet a minimum level of clinically measured change as defined by researchers.

Research on Combination Formulations (Tramadol/Paracetamol)

Research has explored the fixed-dose combination with paracetamol for use in conditions involving periods of heightened symptoms. These trials compared the combination to its individual components and to inactive treatment. Research in this area helps contextualize how patients reported their experience, but limitations exist as comparative evidence is lacking or inconsistent against other treatments in certain chronic contexts.


Gaps in Research and Uncertainty

Scientific reviews and regulatory reports indicate that evidence quality varies across studies and that findings were mixed in some chronic pain conditions. A key limitation is the short follow-up durations of most controlled trials relative to the chronic nature of the conditions being studied. Research has not fully characterized the long-term durability of the observed response.

The available research, while comprehensive in scope for short-term use, highlights what is known — and what is still uncertain — regarding the use of Tramal over an extended duration. Subgroup findings are uncertain, meaning that data for certain groups remain insufficient or not fully characterized by controlled trials.

Frequently Asked Questions (FAQ)

Common questions about Tramal (FAQ)

Q: How quickly does Tramal start to work after taking it?

Official pharmacokinetic studies indicate that the immediate-release form of Tramal generally begins to relieve pain within one hour of ingestion. The drug and its primary active metabolite typically reach their highest concentrations in the bloodstream approximately two to three hours after a dose.

Q: Can Tramal affect my mood or cause anxiety?

Official safety information indicates that Tramal can be associated with certain psychiatric disturbances. These have been documented to include changes in mood, nervousness, and anxiety. Patients who experience these effects are typically advised to discuss them with their healthcare provider.

Q: Can Tramal interact with herbal supplements or vitamins?

Regulatory guidance advises patients to disclose all medications, including vitamins and herbal supplements, to their prescriber. This is crucial because certain supplements can affect how the body processes Tramal or increase the risk of serious pharmacodynamic interactions.

Q: Is Tramal the same as paracetamol (acetaminophen) or ibuprofen?

No, Tramal (tramadol) is classified as a synthetic opioid analgesic that works centrally on the nervous system. Paracetamol (acetaminophen) and ibuprofen are non-opioid pain relievers. However, Tramal is commonly formulated as a fixed-dose combination with paracetamol.

Q: Can Tramal be taken with over-the-counter cold and flu medicine?

Caution is advised because many common over-the-counter (OTC) products contain ingredients that can interact with Tramal. For instance, some ingredients, such as dextromethorphan (a serotonergic drug), can increase the risk of a serious condition called serotonin syndrome when combined with Tramal.

Q: Is it normal to feel a bit dizzy when first starting Tramal?

Yes, official regulatory documents list dizziness as a very common side effect of Tramal. Product information notes that some adverse effects, including dizziness and nausea, are often reported more frequently when a patient first begins taking the medication.

Q: What happens if I forget to take a dose of Tramal?

Official administration instructions for a missed dose are outlined on the product label and vary depending on the specific formulation being used. Patients should refer to the instructions provided by their pharmacist or prescriber for guidance on handling a missed dose safely.

Q: How long does Tramal stay in your system?

Pharmacokinetic studies show that the mean terminal elimination half-life of tramadol is approximately 6 to 7 hours for both the parent drug and its active metabolite. Based on this, it takes roughly two days for the medication to be completely cleared from the system.

Q: Is it true that Tramal can affect serotonin levels?

Yes, regulatory labeling indicates that Tramal's mechanism of action involves inhibiting the reuptake of the neurotransmitter serotonin. This action increases the concentration of serotonin in the nervous system, contributing both to its pain relief and its potential risk for serotonin syndrome.

Q: Does Tramal cause tolerance, meaning I might need more over time?

Official safety information notes that with prolonged exposure, the body can develop a tolerance to Tramal. This means that an individual may find that a constant dose becomes less effective over time, which is a common characteristic of opioid analgesics.

Q: Are there any known withdrawal symptoms if I stop taking Tramal suddenly?

Yes, stopping Tramal abruptly after taking it for a long period can lead to withdrawal symptoms. For this reason, official guidance recommends a gradual dose reduction (tapering) when ending treatment to minimize or prevent these effects.

Q: Can Tramal be crushed or chewed, or should it be swallowed whole?

Regulatory documents state that extended-release tablets should not be crushed or chewed. This is because damaging the tablet can cause the medication to be released too quickly, which carries a significant risk. The administration method for all formulations is specific and should be followed exactly as directed on the product label.

Q: Is Tramal safe for use during pregnancy or while breastfeeding?

Use during pregnancy is not recommended by regulatory bodies due to the risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn. Use while breastfeeding is also generally not recommended because the drug passes into breast milk and has not been fully studied in infants.

Q: What is the typical duration of treatment with Tramal?

Official guidance states that treatment should be for the shortest duration that is necessary to achieve pain relief. The extended-release form is specifically indicated for pain requiring daily, around-the-clock, long-term management.

Q: Can Tramal cause itching or skin rash?

Yes, official regulatory safety data lists pruritus (itching) as a documented side effect of Tramal. Other generalized skin reactions, including a rash, are also reported as a common dermatologic side effect.

Q: Is it important to take Tramal with food or on an empty stomach?

Official labeling states that the immediate-release formulation may be taken regardless of food intake. For the extended-release formulation, patients are typically instructed to maintain consistency with food intake, as a high-fat meal can potentially alter the drug’s absorption.

Q: Why is Tramal generally not recommended for children?

Official regulatory warnings state that Tramal is contraindicated (strictly prohibited) in children younger than 12 years of age. This is due to the significant risk of life-threatening respiratory depression, particularly in those who are ultra-rapid metabolizers of the drug.

Q: What kind of monitoring is needed while taking Tramal?

Patients are required to be closely monitored for signs of respiratory depression (slow or shallow breathing) and profound sedation, especially when treatment begins or when the dosage is increased. Monitoring for the development of substance use disorder is also necessary during therapy.

Q: What should I do if a side effect of Tramal is bothering me?

If a patient experiences side effects that are severe or persistent, they are typically advised to contact their healthcare provider. For signs of a medical emergency, such as severe difficulty breathing, seizures, or extreme confusion, immediate emergency medical attention is necessary, as noted in official warnings.

Q: Is the extended-release version of Tramal different from the immediate-release version?

Yes, they differ in their formulation and function. The extended-release form is designed to release the medicine slowly for daily, around-the-clock pain relief. The immediate-release form releases the medicine quickly and is intended for short-term or 'as-needed' pain.

Q: Can taking Tramal cause mouth dryness?

Yes, according to official adverse reaction data, dry mouth is listed as a common side effect of Tramal.

How should Tramal be stored and disposed of?

Official Storage and Disposal Requirements

Storage & handling requirements for Tramal (tramadol) are defined by regulatory agencies to ensure product stability and safety.

Storage & Protection Domain Official Requirement (Label-Based)
Temperature & Environment Store in a closed container at controlled room temperature (e.g., 20 C to 25 C). Protect from excessive heat, freezing, light, and moisture.
Packaging & Stability Keep the medicine in its original container. Do not use the medicine after the expiration date printed on the packaging.
Child Safety Due to the risk of accidental fatal overdose, keep Tramal strictly out of the reach of children. Store in a secure location protected from theft.
Disposal Instructions Do not keep outdated or unused medicine. Dispose of immediately via a drug take-back location, or follow specific government guidelines for controlled substance disposal (e.g., authorized flushing instructions if a take-back option is unavailable).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tramal found in:

A-Z Index: